This is a summary of the European public assessment report (EPAR) for Palonosetron Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Palonosetron Accord. For practical information about using Palonosetron Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Palonosetron Accord is indicated in adults for: - the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, - the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Palonosetron Accord is indicated in paediatric patients 1 month of age and older for: - The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Therapeutic Area (MeSH)
N/AATC Code
A04AA05
ATC Item
palonosetron
Pharmacotherapeutic Group
Antiemetics and antinauseants
Active Substance (Summary)
INN / Common Names
N/AEMA Name
Palonosetron Accord
Medicine Name
Palonosetron Accord
Aliases
N/ANo risk management plan link.
